KRAS and non-small cell lung carcinoma: Sotorasib and adagrasib are both an oral inhibitor to the RAS GTPase family, demonstrating efficacy in inhibiting the KRAS p.G12C mutation in patients with metastatic NSCLC who have previously undergone chemotherapy (± immunotherapy).